Details:

Alternative Title:
PLoS One
Publisher's site:
http://dx.doi.org/10.1371/journal.pone.0183391
Personal Author:
Kittikraisak, Wanitchaya; Suntarattiwong, Piyarat; Ditsungnoen, Darunee; Pallas, Sarah E.; Abimbola, Taiwo O.; ... More +
Kittikraisak, Wanitchaya; Suntarattiwong, Piyarat; Ditsungnoen, Darunee; Pallas, Sarah E.; Abimbola, Taiwo O.; Klungthong, Chonticha; Fernandez, Stefan; Srisarang, Suchada; Chotpitayasunondh, Tawee; Dawood, Fatimah S.; Olsen, Sonja J.; Lindblade, Kim A.; Less -
Description:
Background Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand. Methods A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012–2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups. Results Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained). Conclusion The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population.
Subject:
[+]
Child, Preschool
Cohort Studies
Cost-Benefit Analysis
Decision Support Techniques
Humans
Infant
Influenza Vaccines
Prospective Studies
Quality-Adjusted Life Years
Seasons

Source:
PLoS One. 12(8).;
Pubmed ID:
28837594
Pubmed Central ID:
PMC5570265
Document Type:
Journal Article;
Place as Subject:
Thailand;
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:52424dc06aedd05c082d55c55350b96415eb6095f3b9af734d347261c6081c05
File Type:

Supporting Files

• 	pone.0183391.t001.gif	gif
  	pone.0183391.t001.jpg	jpeg
  	pone.0183391.t002.gif	gif
  	pone.0183391.t002.jpg	jpeg
  	pone.0183391.g001.gif	gif
  	pone.0183391.g001.jpg	jpeg
  	pone.0183391.g002.gif	gif
  	pone.0183391.g002.jpg	jpeg
  	pone.0183391.nxml	bin
  	pone.0183391.s001.xlsx	xlsx
  	pone.0183391.s002.docx	docx
  	pone.0183391.s003.xlsx	xlsx

More +